Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.42 |
| ▸ | FHIT | P49789 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1431368 | 0.84 | ALDH1A1 (0.47) | ALDH1A1CYP1A2HPGDMAPTGAA | |
| SCHEMBL4297175 | 0.83 | ALDH1A1 (0.46) | ALDH1A1CYP1A2HPGDMAPTGAA | |
| SCHEMBL4129141 | 0.82 | FBP1 (0.62) | ALDH1A1CYP1A2FBP1COPS5 | |
| SCHEMBL1096595 | 0.82 | ALDH1A1 (0.51) | ALDH1A1CYP1A2HPGDMAPTGAA | |
| SCHEMBL4296900 | 0.81 | ALDH1A1 (0.45) | ALDH1A1CYP1A2HPGDMAPTGAA | |
| SCHEMBL289441 | 0.80 | ALDH1A1 (0.73) | ALDH1A1CYP1A2HPGDMAPTGAA | |
| SCHEMBL1431975 | 0.79 | ALDH1A1 (0.43) | ALDH1A1CYP1A2HPGDMAPTGAA | |
| SCHEMBL3119761 | 0.79 | ALDH1A1 (1.00) | ALDH1A1CYP1A2HPGDMAPTGAA | |
| Bromide SCHEMBL16637333 | 0.79 | ALDH1A1 (0.71) | ALDH1A1CYP1A2HPGDMAPTGAA | |
| SCHEMBL1430707 | 0.78 | ALDH1A1 (0.42) | ALDH1A1CYP1A2HPGDMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984360-B1 | Compounds and methods for modulating FX-receptors | LILLY CO ELI (US) | 2014-01-15 | — | — | EP | disclosed |
| CN-101374834-B | Compounds and methods for modulating FXR | ELI LILLY AND CO. (US) | 2011-12-14 | — | — | CN | disclosed |
| US-7863302-B2 | Compounds and methods for modulating FX-receptors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| CN-101374834-A | Compounds and methods for modulating FXR | LILLY CO ELI (US) | 2009-02-25 | — | — | CN | disclosed |
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2008-12-11 | — | — | US | disclosed |
| EP-1984360-A2 | COMPOUNDS AND METHODS FOR MODULATING FX-RECEPTORS | Eli Lilly & Company (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1896048-A2 | PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE (PACAP) RECEPTOR (VPAC2) AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | Bayer Pharmaceuticals Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1883419-A2 | GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | Bayer Pharmaceuticals Corporation (US) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007092751-A2 | COMPOUNDS AND METHODS FOR MODULATING FX-RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2006121588-A2 | PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE (PACAP) RECEPTOR (VPAC2) AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121904-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121860-A2 | GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006091506-A2 | NEUROPEPTIDE Y4 RECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006049681-A2 | SELECTIVE NEUROPEPTIDE Y2 RECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | ADCYAP1R1, VIPR2, ADCY2 | ALDH1A1 2368/4885CYP1A2 2466/4885HPGD 3019/4885 |
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | F2R, TBXA2R, PTAFR | ALDH1A1 4024/4885CYP1A2 660/4885HPGD 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.